search
Back to results

Efficacy of JAK STAT Pathways Inhibitors in Treatment of Patients With Rheumatoid Arthritis

Primary Purpose

Rheumatoid Arthritis

Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
"apigenin" and "glycyrrhizin"
"glycyrrhizin" and "boswellic acid"
"placebo"
Sponsored by
Adel A.Gomaa
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Rheumatoid Arthritis

Eligibility Criteria

18 Years - 60 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Male or female,ages18-60. Patients who met criteria for the diagnosis of RA Patients who were signed the informed consent form. Exclusion Criteria: Patients with Malignant tumours, Patients with Infectious diseases, Patients with Hematologic diseases. Patients with other rheumatic diseases. Women who are pregnant or breastfeeding. Hypersensitivity to dietary supplement used in this study. Hypertensive patients

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm 3

    Arm Type

    Active Comparator

    Active Comparator

    Placebo Comparator

    Arm Label

    "apigenin" and "glycyrrhizin"

    "boswellic acid" and "glycyrrhizin"

    "placebo"

    Arm Description

    Patients will receive one capsule contains 10 mg of apigenin (Matricaria chamomilla L extract) and one capsule contains glycyrrhizin 50(licorice extract) twice daily for 6 months

    Patients will receive one capsule contains 200 mg boswellic acid (Boswellia serrata extract) and one capsule contains glycyrrhizin 50(licorice extract) twice daily for 6 months

    Patients will receive daily two capsules contain placebo for 6 months

    Outcomes

    Primary Outcome Measures

    The change in DAS28 based on C-reactive protein (DAS28-CRP)
    DAS-28 score: a DAS-28 score > 5.1 indicating high disease activity; 3.2< DAS-28 score≤5.1 indicates moderate disease activity; 2.6< DAS-28 score≤3.2 indicates low disease activity; DAS-28 score≤2.6 indicates basic disease remission

    Secondary Outcome Measures

    Change in visual analogue scale (VAS
    each patient will be asked to indicate his or her current level of pain on 100mm scale.0scale indicate no pain and 100mm indicate worst pain imaginable
    Determination of effusion synovitis volume on musculoskeletal ultrasound(MSUS)
    Determination of effusion synovitis volume on musculoskeletal ultrasound
    Determination of Inflammatory cytokines levels: (Tumour necrosis factor α and Interleukin 6).
    laboratory test

    Full Information

    First Posted
    February 27, 2023
    Last Updated
    March 27, 2023
    Sponsor
    Adel A.Gomaa
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05788705
    Brief Title
    Efficacy of JAK STAT Pathways Inhibitors in Treatment of Patients With Rheumatoid Arthritis
    Official Title
    Evaluation of the Efficacy of Natural JAK_ STAT Pathways Inhibitors in Treatment of Patients With Rheumatoid Arthritis as a Complementary Medicine
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    March 2023
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    July 2023 (Anticipated)
    Primary Completion Date
    July 2025 (Anticipated)
    Study Completion Date
    December 2025 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor-Investigator
    Name of the Sponsor
    Adel A.Gomaa

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No

    5. Study Description

    Brief Summary
    There is no treatment that could utterly cure Rheumatoid arthritis (RA), but the disease is mainly improved by conventional disease-modifying anti rheumatic drugs. Methotrexate and biological DMARDs as JAK-STAT inhibitors may be used to control and delay the progression of the disease and improve the quality of lives of patients. However, DMARDs have deleterious effects on human health. Several natural components have JAK-STAT inhibitory effect such as Boswellic acid (Boswellia serrata extract), Glycyrrhizin (Glycyrrhiza glabra extr.) and Apigenin (Chamomile extr)
    Detailed Description
    Rheumatoid arthritis (RA) is a systemic chronic, progressive, autoimmune disease characterized by inflammatory cell infiltration and synovial proliferation, accompanied by injury to articular cartilage and subchondral bone The prevalence of RA in women is 3.6% and 1.7% for men . There is no treatment that could utterly cure RA, but the disease is mainly improved by conventional disease-modifying antirheumatic drugs. Methotrexate and biological DMARDs as JAK-STAT inhibitors may be used to control and delay the progression of the disease and improve the quality of lives of patients. However, DMARDs have deleterious effects on human health. Chronic use of these agents by pregnant patients may induce teratogenic effects . Many studies showed that some natural plant extracts or mixed herbal compounds effectively regulate the immune system and possess in vitro and/or in vivo inhibitory effects against STAT to alleviate RA by inhibiting pro-inflammatory cytokines. Several natural components have JAK-STAT inhibitory effect such as Boswellic acid (Boswellia serrata extract), Glycyrrhizin (Glycyrrhiza glabra extr.) and Apigenin (Chamomile extr.). Boswellic acid and its derivative acetyl-11- keto boswellic acid, are reported to be the most potent inhibitors in the synthesis of 5-LOX. Since 5-LOX is an important enzyme involved in the biosynthesis of leukotrienes and is significantly expressed in RA. B. serrata extract, when administered orally, inhibits IL-6, IL-1 , IFN- TNF- and PGE2 in complete Freund's adjuvant-induced arthritis in rats. Glycyrrhizin reduced the activity of JAK/STAT signaling pathway, which is the upstream regulator of HMGB1. These natural products have inhibitory effect for the STAT3 signaling pathway that have anti-inflammatory and anti-rheumatoid as well as anticancer effects. These inhibitors have been found to inhibit the STAT3 signaling pathway by reducing IL-6 production . Apigenin is a plant-derived flavonoid that is abundant in celery, Chamomile, plantain seed, and is effective in the prevention and treatment of inflammatory diseases, prostate cancer, and in inhibiting tumorigenesis and angiogenesis in melanoma, breast, skin, and colon cancers. Apigenin reduced p-JAK1/2 and p-STAT3 in breast cancer (BT-474) cells, and demonstrated antirheumatic and anticancer activity by inhibiting JAK-STAT . our aim To assess the efficacy of some natural JAK-STAT inhibitors as complementary medicine in the treatment of rheumatoid arthritis and attenuation of the side effects of regular methotrexate our Research outcome measures: Primary (main): The change in DAS28 based on C-reactive protein (DAS28-CRP) and the Clinical Disease Activity Index (CDAI) Rate of achieving 20%, 50% and 70% improvement in the American College Rheumatology criteria (ACR20, ACR50, ACR70). Secondary (subsidiary): Change in visual analogue scale (VAS). Determination of effusion synovitis volume on musculoskeletal ultrasound(MSUS) Determination of Inflammatory cytokines levels: (Tumour necrosis factor α and Interleukin 6). Safety and Tolerability Measures: adverse events including nausea, vomiting, dizziness and abdominal pain, CBC and urine analysis as well as kidney and liver function tests will be performed before enrolment.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Rheumatoid Arthritis

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantOutcomes Assessor
    Allocation
    Randomized
    Enrollment
    75 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    "apigenin" and "glycyrrhizin"
    Arm Type
    Active Comparator
    Arm Description
    Patients will receive one capsule contains 10 mg of apigenin (Matricaria chamomilla L extract) and one capsule contains glycyrrhizin 50(licorice extract) twice daily for 6 months
    Arm Title
    "boswellic acid" and "glycyrrhizin"
    Arm Type
    Active Comparator
    Arm Description
    Patients will receive one capsule contains 200 mg boswellic acid (Boswellia serrata extract) and one capsule contains glycyrrhizin 50(licorice extract) twice daily for 6 months
    Arm Title
    "placebo"
    Arm Type
    Placebo Comparator
    Arm Description
    Patients will receive daily two capsules contain placebo for 6 months
    Intervention Type
    Dietary Supplement
    Intervention Name(s)
    "apigenin" and "glycyrrhizin"
    Intervention Description
    "apigenin" will be administered as capsule (10mg,eq 200mg Matricaria chamomilla L extract) two times daily. Also, "glycyrrhizin " will be administered as capsule(50 mg eq 250 mg licorice extract) two times daily. The two types of capsules administration will be continue for 6 months
    Intervention Type
    Dietary Supplement
    Intervention Name(s)
    "glycyrrhizin" and "boswellic acid"
    Intervention Description
    "boswellic acid" will be administered as capsule (200mg,eq 250mg Boswellia serrata extract) two times daily. Also, "glycyrrhizin " will be administered as capsule(50 mg eq 250 mg licorice extract) two times daily. The two types of capsules administration will be continue for 6 months
    Intervention Type
    Dietary Supplement
    Intervention Name(s)
    "placebo"
    Intervention Description
    "Placebo "capsule will be administered two times daily for 6 months
    Primary Outcome Measure Information:
    Title
    The change in DAS28 based on C-reactive protein (DAS28-CRP)
    Description
    DAS-28 score: a DAS-28 score > 5.1 indicating high disease activity; 3.2< DAS-28 score≤5.1 indicates moderate disease activity; 2.6< DAS-28 score≤3.2 indicates low disease activity; DAS-28 score≤2.6 indicates basic disease remission
    Time Frame
    Before the intervention, 3 months after the intervention, and 6 months after the intervention
    Secondary Outcome Measure Information:
    Title
    Change in visual analogue scale (VAS
    Description
    each patient will be asked to indicate his or her current level of pain on 100mm scale.0scale indicate no pain and 100mm indicate worst pain imaginable
    Time Frame
    Before the intervention, 3 months after the intervention, and 6 months after the intervention
    Title
    Determination of effusion synovitis volume on musculoskeletal ultrasound(MSUS)
    Description
    Determination of effusion synovitis volume on musculoskeletal ultrasound
    Time Frame
    Before the intervention, 3 months after the intervention, and 6 months after the intervention
    Title
    Determination of Inflammatory cytokines levels: (Tumour necrosis factor α and Interleukin 6).
    Description
    laboratory test
    Time Frame
    Before the intervention, 3 months after the intervention, and 6 months after the intervention

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    60 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Male or female,ages18-60. Patients who met criteria for the diagnosis of RA Patients who were signed the informed consent form. Exclusion Criteria: Patients with Malignant tumours, Patients with Infectious diseases, Patients with Hematologic diseases. Patients with other rheumatic diseases. Women who are pregnant or breastfeeding. Hypersensitivity to dietary supplement used in this study. Hypertensive patients
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Adel A Gomaa, ph.D
    Phone
    01009534841
    Email
    a.gomaa@aun.edu.eg
    First Name & Middle Initial & Last Name or Official Title & Degree
    Safaa A Mahran, MD
    Phone
    01003385106
    Email
    Safaa69@yahoo.com

    12. IPD Sharing Statement

    Plan to Share IPD
    Yes
    IPD Sharing Plan Description
    Data will become available to interested investigators upon submitting a reasonable research request by email to A. Gomaa (a.gomma@aun.edu.eg).
    IPD Sharing Time Frame
    July, 2025
    IPD Sharing Access Criteria
    Data will become available to interested investigators upon submitting a reasonable research request by email to A. Gomaa (a.gomma@aun.edu.eg).
    Citations:
    PubMed Identifier
    27156434
    Citation
    Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016 Oct 22;388(10055):2023-2038. doi: 10.1016/S0140-6736(16)30173-8. Epub 2016 May 3. Erratum In: Lancet. 2016 Oct 22;388(10055):1984.
    Results Reference
    background
    PubMed Identifier
    29736302
    Citation
    Guo Q, Wang Y, Xu D, Nossent J, Pavlos NJ, Xu J. Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. Bone Res. 2018 Apr 27;6:15. doi: 10.1038/s41413-018-0016-9. eCollection 2018.
    Results Reference
    background
    PubMed Identifier
    31987685
    Citation
    Oton T, Carmona L. The epidemiology of established rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2019 Oct;33(5):101477. doi: 10.1016/j.berh.2019.101477. Epub 2020 Jan 25.
    Results Reference
    background
    PubMed Identifier
    35081280
    Citation
    Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, Germino R, Menon S, Sun Y, Wang C, Shapiro AB, Kanik KS, Connell CA; ORAL Surveillance Investigators. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. N Engl J Med. 2022 Jan 27;386(4):316-326. doi: 10.1056/NEJMoa2109927.
    Results Reference
    background
    PubMed Identifier
    36198438
    Citation
    Hoisnard L, Pina Vegas L, Dray-Spira R, Weill A, Zureik M, Sbidian E. Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study. Ann Rheum Dis. 2023 Feb;82(2):182-188. doi: 10.1136/ard-2022-222824. Epub 2022 Oct 5.
    Results Reference
    background
    PubMed Identifier
    35868477
    Citation
    Yang J, Wang L, Guan X, Qin JJ. Inhibiting STAT3 signaling pathway by natural products for cancer prevention and therapy: In vitro and in vivo activity and mechanisms of action. Pharmacol Res. 2022 Aug;182:106357. doi: 10.1016/j.phrs.2022.106357. Epub 2022 Jul 19.
    Results Reference
    background
    PubMed Identifier
    30149545
    Citation
    Dudics S, Langan D, Meka RR, Venkatesha SH, Berman BM, Che CT, Moudgil KD. Natural Products for the Treatment of Autoimmune Arthritis: Their Mechanisms of Action, Targeted Delivery, and Interplay with the Host Microbiome. Int J Mol Sci. 2018 Aug 24;19(9):2508. doi: 10.3390/ijms19092508.
    Results Reference
    background
    PubMed Identifier
    31041173
    Citation
    Kumar R, Singh S, Saksena AK, Pal R, Jaiswal R, Kumar R. Effect of Boswellia Serrata Extract on Acute Inflammatory Parameters and Tumor Necrosis Factor-alpha in Complete Freund's Adjuvant-Induced Animal Model of Rheumatoid Arthritis. Int J Appl Basic Med Res. 2019 Apr-Jun;9(2):100-106. doi: 10.4103/ijabmr.IJABMR_248_18.
    Results Reference
    background
    PubMed Identifier
    29568761
    Citation
    Wu X, Wang W, Chen Y, Liu X, Wang J, Qin X, Yuan D, Yu T, Chen G, Mi Y, Mou J, Cui J, Hu A, E Y, Pei D. Glycyrrhizin Suppresses the Growth of Human NSCLC Cell Line HCC827 by Downregulating HMGB1 Level. Biomed Res Int. 2018 Jan 15;2018:6916797. doi: 10.1155/2018/6916797. eCollection 2018.
    Results Reference
    background
    PubMed Identifier
    35082907
    Citation
    Wu Y, Wang Z, Du Q, Zhu Z, Chen T, Xue Y, Wang Y, Zeng Q, Shen C, Jiang C, Liu L, Zhu H, Liu Q. Pharmacological Effects and Underlying Mechanisms of Licorice-Derived Flavonoids. Evid Based Complement Alternat Med. 2022 Jan 17;2022:9523071. doi: 10.1155/2022/9523071. eCollection 2022.
    Results Reference
    background
    PubMed Identifier
    35807549
    Citation
    Abid R, Ghazanfar S, Farid A, Sulaman SM, Idrees M, Amen RA, Muzammal M, Shahzad MK, Mohamed MO, Khaled AA, Safir W, Ghori I, Elasbali AM, Alharbi B. Pharmacological Properties of 4', 5, 7-Trihydroxyflavone (Apigenin) and Its Impact on Cell Signaling Pathways. Molecules. 2022 Jul 4;27(13):4304. doi: 10.3390/molecules27134304.
    Results Reference
    background

    Learn more about this trial

    Efficacy of JAK STAT Pathways Inhibitors in Treatment of Patients With Rheumatoid Arthritis

    We'll reach out to this number within 24 hrs